Vaxart Files Proxy Materials, No Fee Required
Ticker: VXRT · Form: DEFA14A · Filed: Apr 10, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | DEFA14A |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, administrative
TL;DR
Vaxart filed proxy docs, no fee. Shareholders get updates.
AI Summary
Vaxart, Inc. filed a Definitive Additional Materials (DEFA14A) on April 10, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is based in South San Francisco, CA.
Why It Matters
This filing provides important information to shareholders regarding company matters, as detailed in the proxy statement, and signals the company's ongoing compliance with SEC regulations.
Risk Assessment
Risk Level: low — This filing is a routine administrative document (DEFA14A) and does not contain new financial or strategic information that would typically impact risk.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
- 20250410 (date) — Filing date
FAQ
What type of filing is this DEFA14A for Vaxart, Inc.?
This filing is classified as Definitive Additional Materials (DEFA14A).
When was this filing submitted to the SEC?
The filing was submitted on April 10, 2025.
Was there a filing fee associated with this DEFA14A filing?
No fee was required for this filing.
What is Vaxart, Inc.'s primary business address?
Vaxart, Inc.'s business address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080.
What were some of Vaxart, Inc.'s previous company names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 10, 2025 regarding Vaxart, Inc. (VXRT).